Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“When fibrinogen isn’t really fibrinogen…
A ‘normal’ or even elevated fibrinogen result can be reassuring.
But what if that number isn’t telling the full story?
Welcome to one of the most overlooked pitfalls in coagulation testing
The Clauss fibrinogen assay – trusted, but not foolproof
The Clauss method measures functional fibrinogen by assessing clot formation after high thrombin concentration.
But here’s the catch:
It assumes fibrinogen is functionally normal
When it’s not… results can mislead.
Dysfibrinogenemia: the great imitator
In dysfibrinogenemia, fibrinogen antigen levels may be normal… but function is impaired.
What you might see:
Discrepancy between Clauss fibrinogen (low) and antigen (normal)
Unexplained bleeding… or paradoxically, thrombosis
Prolonged clotting times (sometimes subtle, sometimes not)
In other words:
There is fibrinogen present — it just doesn’t work properly
But it’s not always dysfibrinogenemia…
The Clauss assay can be affected by multiple interferences:
- Direct thrombin inhibitors (e.g. dabigatran)
- Heparin (depending on reagent sensitivity)
- High FDPs / D-dimer
- Paraproteins
- Severe inflammation
All of these can – falsely low functional fibrinogen
So what should you do?
- Correlate with clinical context
- Compare functional vs antigen fibrinogen
- Review medications and interferences
- Consider reptilase time or genetic testing if needed
Take-home message
Not all fibrinogen results reflect true functional capacity.
Sometimes, what looks like ‘low fibrinogen’ is actually a measurement limitation – or a dysfunctional molecule hiding in plain sight.
Want more clear, practical insights into coagulation testing pitfalls?”

More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026